Ongoing Clinical Trials for Transferrin Decreased
There is currently 1 ongoing clinical trial investigating treatment options for transferrin decreased, a rare condition also known as atransferrinemia or hypotransferrinemia. This trial is testing a therapy called Human Apotransferrin and is being conducted across multiple European locations including Germany, Italy, and Spain.
Clinical trial locations
- Germany
- Italy
- Spain
Study on the Use of Human Apotransferrin for Treating Patients with Atransferrinemia
This clinical trial is investigating Human Apotransferrin as a treatment for atransferrinemia, a rare blood disorder where the body has very low levels of transferrin, a protein essential for transporting iron in the blood. The treatment is given as a solution through an intravenous infusion, meaning it is delivered directly into the bloodstream through a vein.
Who can participate:
- Patients must have a confirmed diagnosis of atransferrinemia with transferrin levels below 40 mg/dL
- Both male and female participants of all ages are eligible
- Participants must be willing and able to sign an informed consent document
- Patients must be able to follow study procedures and attend appointments
Who cannot participate:
- Patients who do not have congenital atransferrinemia or hypotransferrinemia
- Those who fall outside the specified age range for the study
- Patients who are unable or unwilling to follow study procedures
- Those with other medical conditions that might interfere with the study or pose safety risks
What the study involves:
The main goal of this trial is to evaluate how the body processes Human Apotransferrin, as well as its effectiveness and safety in treating atransferrinemia. Participants will receive different doses of the therapy to help determine the most effective and safe dosage.
The study will monitor important blood components such as hemoglobin and hematocrit, which are indicators of healthy blood function. Researchers will also assess how the treatment affects iron levels throughout the body, including in the liver and heart, to ensure there is no dangerous iron buildup. Regular check-ups will be conducted to assess how participants respond to treatment and to monitor any side effects.
Investigational drug:
The therapy being tested is Apotransferrin, a protein-based treatment that works by binding to free iron in the blood and helping transport it to cells where it is needed. The solution contains 50g/l of human apotransferrin. This treatment aims to replace the missing or deficient transferrin protein in patients with atransferrinemia, allowing iron to be properly distributed throughout the body rather than accumulating in organs.
The study is estimated to conclude by January 2028 and will provide important information about how Human Apotransferrin can help manage this rare condition and potentially improve quality of life for those affected.
Summary
Currently, there is one active clinical trial focused on transferrin decreased, specifically targeting atransferrinemia. This trial represents an important research effort for this rare genetic disorder and is being conducted across three European countries: Germany, Italy, and Spain. The study focuses on Human Apotransferrin as an investigational therapy, which aims to replace the missing protein that is essential for proper iron transport in the body. The trial is designed to evaluate different dosages to establish both safety and effectiveness, with particular attention to preventing iron overload in vital organs while improving blood health indicators. With an estimated completion date in 2028, this research offers hope for better treatment options for patients living with this challenging condition.
